TRENDING :  Market Movers  |  Top 50   SPY (0.09%)    CGC (8.29%)    CASY (-1.42%)    BABA (-0.84%)    BA (-1.29%)    ATVI (0.07%)    ARCW (-0.88%)    APC (-0.19%)    SPG (-2.45%)    SCIF (-2.32%)    RYAAY (-2.36%)    PANW (1.63%)    PAGS (1.51%)    MU (0%)    MMYT (-0.2%)    MJ (3.05%)    MHK (-0.29%)    MBRX (168.47%)    M (-3%)    INTC (0.57%)    GOOGL (0.99%)    GDXJ (-2.07%)    FRT (-1.98%)    FIS (1.2%)    EWZ (0.08%)

 AZN - Astrazeneca PLC

$38.75 [-0.05][-0.13%]

Next Earnings

5/17/2019

BMO

Recommend
Trade Idea »



ANALYST RATINGS

Quarterly Rating Chart
Rating

1


1=Strong Buy, 2=Buy, 3=Hold, 4=Underperform, 5=Sell
Price Targets
High $48.00
Low $48.00
Average $48.00
Current $38.75

CompanyAnalyst NamePT ActionActionRatingTargetDate
Cowen & Co.RaisesUpgradesStrong Buy$48.0004/01/19
*Last 90 days

OPEN RECOMMENDATIONS

No recommendations found.


This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.

TRADERS TRACKING $AZN

TRENDING ARTICLES



AVEO Pharmaceuticals Down More Than 40% in 90 Days: Here's Why

04/18/19
Shares of AVEO Pharmaceuticals Inc AVEO have witnessed a sharp decline in the past three months underperforming its industry In fact the biotech stock has plunged 43 2 wider than the industry s decline of 3 5 Notably this January AVEO faced a major setback when it had to

AstraZeneca Breaks Below 200-Day Moving Average - Notable for AZN

04/17/19
In trading on Wednesday shares of AstraZeneca plc Symbol AZN crossed below their 200 day moving average of 38 84 changing hands as low as 38 73 per share AstraZeneca plc shares are currently trading off about 1 1 on the day The chart below shows the one year performance of AZN

Top Ranked Income Stocks to Buy for April 17th

04/17/19
Here are four stocks with buy rank and strong income characteristics for investors to consider today April 17th Hi Crush Partners LP HCLP This proppant and logistics solutions provider has witnessed the Zacks Consensus Estimate for its current year earnings increasing 57 1 over the last

Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer

04/15/19
Clovis Oncology Inc CLVS in a SEC filing announced the discontinuation of a phase II ATLAS study evaluating Rubraca rucaparib monotherapy for treating recurrent metastatic bladder cancer The decision is based on a recommendation from an independent data monitoring committee

Dow 30 Stock Roundup: Procter & Gamble Hikes Dividend, Boeing Q1 Commercial Deliveries Fall

04/12/19
The index traversed a lackluster trading week as investors looked toward first quarter earnings numbers for direction Developments on the trade war front continued to determine investor sentiment to some extent The latest Fed minutes reaffirmed its recent dovish stance providing some respite

Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal

04/12/19
This was a relatively light week in terms of news in the pharma sector ahead of the first quarter earnings season While Glaxo GSK gained FDA approval for a new two drug HIV medicine for previously untreated patients AstraZeneca AZN Merck s MRK PARP inhibitor Lynparza was approved for

Is AstraZeneca Stock Worth Buying Before Earnings?

04/10/19
InvestorPlace Stock Market News Stock Advice amp Trading Tips Last year s extreme sentiment fears have abated and now the equity markets are back near all time highs This includes stocks like AstraZeneca NYSE AZN as it set a new high late last month From

Alkermes Reports Positive Data From Schizophrenia Study

04/10/19
Alkermes plc ALKS announced positive top line results from ALPINE Aripiprazole 160 Lauroxil and 160 Paliperidone palmitate 160 INitiation 160 Effectiveness a six month phase IIIb study evaluating the efficacy safety and tolerability of its long acting

AstraZeneca/Merck's Lynparza Wins EU Nod for Breast Cancer

04/10/19
AstraZeneca plc AZN and partner Merck MRK announced that the European Commission has approved their PARP inhibitor Lynparza olaparib as a monotherapy for a new patient population suffering germline BRCA mutated HER2 negative locally advanced metastatic breast cancer previously treated

J&J (JNJ) to Kick-start Pharma Q1 Earnings: What's in Store?

04/10/19
Johnson amp Johnson JNJ will report first quarter 2019 results on Apr 6 before market open In the las t report ed quarter the company delivered a positive earnings surprise of 1 03 J amp J s performance has been pretty impressive with the company exceeding earnings expectations in

Pre-Market Most Active for Apr 10, 2019 : ATAI, AMD, AZN, AAPL, LYG, HUYA, QQQ, TEVA, ALC, LEVI, SQQQ, ERIC

04/10/19
The NASDAQ 100 Pre Market Indicator is up 7 32 to 7 575 81 The total Pre Market volume is currently 4 380 681 shares traded The following are the most active stocks for the pre market session ATA Inc ATAI is 0 77 at 2 89 with 900 395 shares traded Advanced

Mid-Afternoon Market Update: Dow Down Over 200 Points; Precipio Shares Spike Higher

04/09/19
Toward the end of trading Tuesday the Dow traded down 0 8 percent to 26130 23 while the NASDAQ declined 0 51 percent to 7913 01 The S amp P also fell dropping 0 68 percent to 2 876 04 Leading and Lagging Sectors Tuesday afternoon the utilities shares rose 0 1 percent

Mid-Morning Market Update: Markets Open Lower; PhaseBio Gets Breakthrough Therapy Designation For PB2452

04/09/19
Following the market opening Tuesday the Dow traded down 0 7 percent to 26156 96 while the NASDAQ declined 0 2 percent to 7938 18 The S amp P also fell dropping 0 5 percent to 2 881 67 Leading and Lagging Sectors Tuesday morning the utilities shares slipped by just 0 05

PhaseBio Stock Up on Breakthrough Therapy Status for PB2452

04/09/19
PhaseBio Pharmaceuticals Inc PHAS announced that the FDA has granted Breakthrough Therapy designation to its lead pipeline candidate PB2452 The company is developing the candidate in an early stage study as a reversal agent for an antiplatelet drug AstraZeneca s AZN Brilinta

Inovio Earns 3rd Milestone Fee From AstraZeneca for MEDI0457

04/09/19
Inovio Pharmaceuticals Inc INO announced that it has received an undisclosed milestone payment from AstraZeneca AZN as the latter dosed the first patient in a phase II study on the T cell activating immunotherapy MEDI0457 The study will evaluate MEDI0457 in combination with AstraZeneca